JianShi Medical's iREACH IRIS stapler receives CE certification, AI pulmonary nodule surgical navigation system advances overseas registration
JianShi Medical's iREACH IRIS intelligent electric endoscopic stapler, Ruiyan scissor-type integrated ultrasonic scalpel, and OMNIVUE 4K+3D+fluorescence three-in-one endoscopic camera system have obtained CE certification in the EU and been launched, among which iREACH IRIS has entered top hospitals such as Germany's Charité Hospital and the University of Cambridge affiliated hospitals in the UK. More than 70% of the company's overseas sales revenue this year comes from developed country markets, and it is advancing overseas registration and market access for its AI pulmonary nodule surgical navigation system, which recently obtained domestic certification.
Body · AI translation
On October 19, the GenSuite Global Partner Conference was held in Wuxi for the third consecutive year. More than 100 distributor representatives from 31 countries around the world attended the event and visited the GenSuite Wuxi Clinical Training Center to learn about the clinical training system and development potential of Chinese medical device companies.
This year, a number of products independently developed by GenSuite Surgical, including the iREACH IRIS intelligent powered endoscopic stapler (abbreviated as: iREACH IRIS), the Ruiyan™ scissor-type integrated ultrasonic scalpel, and the OMNIVUE "4K+3D+fluorescence three-in-one endoscopic camera system," obtained CE certification in the European Union and were launched, receiving positive evaluations from European clinical users.
Among them, iREACH IRIS features a "tissue-adaptive real-time feedback function" and can accommodate GenSuite's globally pioneering 90° large articulation angle reload, and is accelerating its deployment in overseas hospitals. Multiple European distributors stated that local doctors highly recognize the product's clinical advantages in highly difficult procedures such as low rectal cancer surgery, and it has quickly entered a number of top hospitals, including Charité in Germany and Cambridge University Hospitals in the United Kingdom. This year, more than 70% of GenSuite's overseas sales revenue came from developed-country markets.
The image shows overseas distributors trying out the iREACH IRIS stapler
At the conference, five doctors from Germany, the United Kingdom, Spain, and Japan held a roundtable discussion on topics including device innovation, market access, and clinical training needs. Dr. Beltrán de la Vega from Spain stated that, against the backdrop of healthcare cost containment, hospital budget constraints, and stricter procurement evaluations in Europe, devices must not only be innovative but also meet health economics evaluation requirements; Chinese medical devices have unique advantages in medical-engineering innovation and offer high quality at attractive prices, which is an important reason they are drawing attention in the European market. Professor Izbicki, widely regarded by the German medical community as a "national treasure-level expert" in surgery, stated that European surgeons, especially young doctors, still have relatively high demand for professional clinical training, and Chinese companies going global should increase relevant investment and services.
In November 2022, GenSuite Medical's clinical training center in Wuxi opened, with annual training capacity of up to 4,000 person-times. Over the past two years, GenSuite has added training centers in Jakarta and Singapore and holds quarterly "master classes" in Europe to conduct clinical surgical training.
The image shows a roundtable discussion with overseas doctors at the GenSuite Global Partner Conference
At the same time, Dr. Wan Shan, CTO of GenSuite Medical, introduced to overseas distributors the "AI pulmonary nodule surgical navigation system" that had newly obtained certification in China. The system uses AI algorithms to match preoperative medical images with intraoperative real-time endoscopic images, helping doctors relocate tiny nodules when lung tissue deforms or collapses, achieving intraoperative precise localization and real-time navigation, and reducing the risk of pain and complications associated with traditional preoperative localization. The company is advancing overseas registration and market access for the product and plans to accelerate overseas deployment by combining it with clinical training.
Wang Xin, Chairman and CEO of GenSuite Medical Technology Group, stated that the core of GenSuite's globalization is not reliance on low-priced products, but on "meaningful innovation" and supporting capabilities such as clinical training and after-sales service, so that innovative devices can truly solve problems in overseas clinical scenarios. The company has established the "G3 Jirui Medical Innovation Platform" in Wuxi, will vigorously develop new devices in the fields of digital surgery, neurointervention, and structural heart disease, and will increase R&D investment in the AI healthcare field, continuously serving doctors around the world with innovative products.